Liquidia Corporation is applying its novel PRINT® technology toward the internal development of two product candidates for which we hold worldwide commercial rights, including:

  • Our lead product candidate, LIQ861, for pulmonary arterial hypertension (PAH). After consultation with the FDA, we advanced LIQ861 from a Phase 1 trial directly to our open-label Phase 3 trial (INSPIRE).
  • LIQ865, for which we have completed two Phase 1 clinical trials for local post-operative pain.
© 2021 Liquidia Corporation